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Lysosomal storage disorders (LSDs) occur at a frequency of 1 in every 5,000 live births and are a common cause
of pediatric neurodegenerative disease. The relatively small number of patients with LSDs and lack of validated
biomarkers are substantial challenges for clinical trial design. Here, we evaluated the use of a commercially
available fluorescent probe, Lysotracker, that can be used to measure the relative acidic compartment volume of
circulating B cells as a potentially universal biomarker for LSDs. We validated this metric in a mouse model of
the LSD Niemann-Pick type C1 disease (NPC1) and in a prospective 5-year international study of NPC patients.
Pediatric NPC subjects had elevated acidic compartment volume that correlated with age-adjusted clinical severity and was reduced in response to therapy with miglustat, a European Medicines Agency–approved drug that
has been shown to reduce NPC1-associated neuropathology. Measurement of relative acidic compartment volume was also useful for monitoring therapeutic responses of an NPC2 patient after bone marrow transplantation. Furthermore, this metric identified a potential adverse event in NPC1 patients receiving i.v. cyclodextrin
therapy. Our data indicate that relative acidic compartment volume may be a useful biomarker to aid diagnosis,
clinical monitoring, and evaluation of therapeutic responses in patients with lysosomal disorders.
Introduction
Lysosomal storage disorders (LSDs) are a group of more than 60
inborn errors of metabolism that result in the expansion of the
late endosomal/lysosomal (LE/Lys) compartment in cells (1–3).
We therefore hypothesized that measuring relative LE/Lys volume
could serve as a potentially universal biomarker for this family of
disorders. To test this hypothesis, we developed an assay using the
fluorescent probe Lysotracker, a weakly basic amine that selectively builds up in the acidic compartment (i.e., LE/Lys). This probe
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can be visualized and quantified in circulating cells and has previously been reported in a single clinical case study of a patient
with adult-onset Niemann-Pick type C disease (NPC) (3). NPC1
is a progressive neurodegenerative LSD caused by mutations in
either NPC1 or NPC2 (4). Diagnosis of NPC, which is technically
challenging, is often delayed. There is currently 1 European Medical Association–approved disease-modifying therapy, miglustat,
which is licensed for treating the CNS manifestations of NPC1,
combined with symptomatic management (5, 6). At the time of
the clinical trial of miglustat, there were no validated biomarkers
for NPC that could be used as secondary endpoints in support
of clinical data. Recently, oxysterols emerged as the first validated
biochemical biomarker for NPC (7, 8).
In this study, we optimized the Lysotracker assay and validated
it in a prospective study of more than 100 NPC patients derived
from multiple independent clinical cohorts to ensure statistical
power. We used this disorder as proof of concept for its use in
other LSDs, due to the relatively large number of patients available to study with this specific lysosomal disorder. We applied this
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Figure 1
Relative LE/Lys volume increases progressively in B cells in a mouse model of NPC1 disease and parallels the rate of GSL storage in the brain.
(A and B) Splenic (A) and circulating (B) B cells were analyzed by flow cytometry over the lifespan of the Npc1–/– mouse (3 weeks, presymptomatic; 6 weeks, early symptomatic; 9 weeks, late symptomatic) and compared with wild-type Npc1+/+ controls. A pan–B cell marker was detected
using an anti-CD19 monoclonal antibody conjugated to PE, and cells were costained with Lysotracker green. Analysis was performed on gated
B cells (CD19+), and Lysotracker staining levels were standardized to fluorescent microbeads conjugated to defined numbers of fluorescent molecules/bead to linearize the logarithmic data collected by the cytometer. There was progressive elevation in B cell MEFL at each time point relative
to the previous age point (P < 0.01, spleen, all ages, and blood, 6 and 9 weeks). (C and D) GSL analysis, performed by HPLC, of GM2 ganglioside
(C) and lactosylceramide (D) in the forebrain of 2-, 4-, 7-, and 9-week-old Npc1–/– mice compared with wild-type controls. **P < 0.01; ***P < 0.001.

assay to small, resting, circulating B cells because they can readily be identified as a uniform population using the CD19 marker
and do not change in response to infection. Circulating B cells are
therefore a suitable cell type to analyze in longitudinal studies. We
found here that this biomarker correlated with age-adjusted clinical severity scores and was responsive to miglustat therapy. It also
correlated with levels of oxysterol (an NPC-specific biochemical
biomarker; ref. 7) in the same patient samples. This biomarker also
showed utility in monitoring response to bone marrow transplantation (BMT) in an NPC2 patient and identified an unanticipated
adverse event in NPC patients receiving cyclodextrin therapy with
i.v. 2-hydroxypropyl-β-cyclodextrin (HPβCD). Taken together, our
data support the use of this biomarker in clinical monitoring of
NPC. In addition, this assay has the potential to be a universal
monitoring tool for any disease with lysosomal hypertrophy.
Results
Assay validation in a mouse model. We first validated the assay in
resting B cells (splenic and circulating) from Npc1–/– mutant mice
using the minimal group size to provide statistically valid results

with enough power (in this case, 3 mice per group per time point).
We quantified Lysotracker fluorescence — calibrated using fluorescent microbead standards and expressed as mean equivalent
of fluorescence (MEFL) — and observed a progressive increase
in relative acidic compartment volume (Figure 1, A and B).
This expansion of LE/Lys was seen at all ages compared with agematched controls and was highly significant at each time point
in both splenic and circulating B cells (P < 0.001). We have previously shown that B cells from Npc1–/– store high levels of glycosphingolipids (GSLs) when measured by HPLC (9). A key finding
was that peripheral B cell storage, as indicated by MEFL, paralleled progressive ganglioside and lactosylceramide storage in the
brain, as measured by HPLC (Figure 1, C and D), which indicates that the rate of storage in B cells in the periphery parallels
storage in the CNS. The probe LipidTOX, which detects phospholipid storage, detected phospholipids in control and Npc1 –/–
B cells, but did not show enhanced staining in Npc1–/– relative to
wild-type B cells (Supplemental Figure 1B; supplemental material available online with this article; doi:10.1172/JCI72835DS1),
and thus was not further evaluated.
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Figure 2
Relative LE/Lys volume identifies pediatric patients with NPC1 disease. Data were collected prospectively on NPC1 patients (n = 97, aged
2 months to 53 years), heterozygous carriers (NPC Het; n = 40, aged 23 to 76 years), age-matched controls (n = 53, aged 4 months to 64 years),
and 2 pediatric patients with Tay-Sachs disease (TS). (A) Lysotracker values from circulating B cells were measured by flow cytometry and plotted
against patient age. Each patient only appears once, standardized to the first sample analyzed for each patient. ***P < 0.01. (B) When the same
patients’ data were plotted as unadjusted severity score (with higher value denoting greater disease burden) against age, multiple subgroups were
identified. These were designated according to decreasing severity, from the severest (subgroup a) to the mildest (subgroup f). Rate of change
per year is indicated for each subgroup. (C) Total severity score (without hearing, as this was not measured by all clinical centers) for each patient
was divided by patient age to generate ASIS. When plotted against MEFL, a statistically significant correlation was found (P = 0.017). (D) When
each patient’s plasma cholestane-3β,5α,6β-triol level was plotted against their MEFL value, a statistically significant correlation was observed
in all patients (P < 0.01). A piecewise linear model significantly improved the goodness-of-fit with respect to a single linear model (P < 0.001); in
this model, the initial slope was significant (P = 0.015), and the second was not (P = 0.228), with the estimated change point being 21,269 MEFL.

Assay validation in patient blood samples. The Lysotracker assay
was then applied to peripheral blood B cells from NPC patients.
Although this assay would in practice be used for monitoring individual patients over time, we had the opportunity here to evaluate
this biomarker at the population level. We found that MEFL values were significantly elevated in B cells from the majority of pediatric NPC1 patients (aged 0–12 years; P < 0.001; Figure 2A); only
4 cases in the 0–6 year age range and 6 cases in the 7–12 year age
range overlapped with control values. 2 infantile Tay-Sachs disease
1322

patients also had elevated levels of MEFL above the age-matched
control range. The youngest NPC1 subjects with significant clinical manifestations had the highest MEFL values (P < 0.05, 0–6
years vs. 13–18 years; P < 0.01, 0–6 years vs. ≥19 years). In contrast,
the adult NPC1 patients (with later onset and slower disease progression) and the heterozygous carriers did not differ significantly
from age-matched controls at the population level (Figure 2A).
Characterization of the study cohort. To better characterize the study
cohort, clinical severity scores (for which higher scores denote
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Figure 3
Miglustat treatment reduces lysosomal storage in NPC1 patients’ B
cells. Box plots summarizing progression of storage for untreated (n = 7),
chronic miglustat (n = 17), and pre-post miglustat (n = 14) patient
groups as well as adult controls (n = 14) analyzed over time. The box
is limited by the 1st and 3rd quartiles (Q1 and Q3), and the median
is indicated by a bar inside the box; whiskers and outliers are defined
in terms of 2 unmarked boundaries defined using Tukey’s rule as
Q1 – 1.5 IQR and Q3 + 1.5 IQR (IQR, interquartile range, i.e., Q3 – Q1).
Whiskers extend to the smallest and largest observed values within the
boundaries, and outliers are defined as points outside the boundaries.
Adjusted pairwise multiple comparisons are shown (Wilcoxon-MannWhitney test). See Table 1 and Supplemental Figure 7.

increasing severity; ref. 10) were plotted against patient age. Hear- plasmas and found a significant correlation in NPC1 patients
ing was excluded, as it was not measured in all clinical centers. (P = 0.015), but not in controls or heterozygous carriers (Figure 2D).
There was no simple linear or nonlinear model that adequately repResponse to treatment with miglustat. Longitudinal data were colresented the complete data distribution (Supplemental Figure 2). lected on 38 patients that were untreated, chronically treated
We therefore looked for discrete subpopulations of patients and with miglustat (>6 months; ref. 5), or analyzed both before and
identified 6 subgroups (denoted a–f), with subgroups b, c, and d after miglustat therapy, with the first point being pretreatment
defined by latent class mixture modeling (Figure 2B). The study (referred to herein as pre-post analysis) (Table 1). There were no
cohort included miglustat-treated patients, which were repre- significant differences in median ages for the 3 groups (P = 0.09).
sented in all 6 subgroups (Supplemental Figures 3 and 4). Sei- Of the untreated patients, 86% had positive slopes (progression of
zures are a common feature in the most severely affected patients; storage), compared with 71% in the chronically miglustat-treated
consistent with this, patients with seizures were almost exclusively group and 43% in the pre-post group (Table 1 and Figure 3).
present in subgroups a–c (Supplemental Figure 5). When a small Untreated adult controls (variable MEFL values) with repeat meanumber of untreated patients were plotted longitudinally, they sures were analyzed, and no significant slopes were detected (Figremained within the same subgroup (Supplemental Figure 6), ure 3 and Supplemental Figure 7).
which suggests that these subgroups may have prognostic value.
Response to BMT in an NPC2 patient. An NPC2 patient was analyzed
When MEFL values were plotted against total clinical severity before and after BMT. Prior to BMT (and before immunosuppresscore, no significant correlation was observed in the group as a sive conditioning), the patient’s MEFL value approximated the
whole or in subgroups a–f (data not
shown). As disease progression has
Table 1
been reported to be linear in NPC
Miglustat treatment slows the rate of storage in NPC1 patients
disease (10), and different patients
achieved their severity scores over
Treatment and
Median age at first Subjects
Positive Negative
No
Median slope
variable numbers of years (Figure
clinical status
measurement (yr) analyzed (n) slope (n) slope (n) slope (n) (MEFL/yr)
2B), total severity scores were dividNPC1 untreated
9.8
7
6
0
1
4,436
ed by age to give an annual severity
NPC1 chronic miglustat
10.9
17
12
3
2
1,849A
increment score (ASIS). When ASIS
NPC1 pre-post miglustat
9.5
14
6
4
4
1,010B,C
was plotted against MEFL, a sigUntreated
adult
controls
43.0
14
6
4
4
998
nificant correlation was observed
for the total NPC1 population
There was no significant difference in the median ages for the 3 NPC1 patient groups (P = 0.65, Kruskal(P = 0.017; Figure 2C), but not after
Wallis test). Ages were not available for all adult controls, but were >18 and <65 years; median based on
n = 6. Slopes were calculated from each patient’s longitudinal data, based on ≥2 repeat measures (untreatstratifying by latent subgroups a–f,
ed, 2–4; pre-post, 2–5; chronic miglustat, 2–6) over time up to 3.0 years (median, last measurement up to
as these were individually under10.92 months after first sample analyzed). Given the small number of repeat measurements, rather than
powered (data not shown).
calculating a P value for each individual slope, subjects with a ±10% difference between first and last MEFL
Relationship to oxysterols. Oxysterols
were defined as stable (no slope). A logistic regression model showed a significant difference between the
proportion of positive slopes (NPC1 untreated, 86%; NPC1 chronic miglustat, 71%; NPC1 pre-post migluhave been validated as NPC-specific
stat, 43%) and nonpositive slopes between the untreated and pre-post groups (P = 0.05). Overall, median
biochemical biomarkers (7, 8). We
slopes from the 3 patient groups were significantly not homogeneous (P = 0.03, Kruskal-Wallis test).
therefore measured cholestaneAP = 0.11 vs. untreated; BP = 0.029 vs. untreated; CP = 0.13 vs. treated; Wilcoxon-Mann-Whitney tests with
3β,5α,6β-triol and MEFL in matched
Benjamini-Hochberg correction for multiple comparisons.
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Figure 4
Relative LE/Lys volume is a sensitive measure of response and potentially adverse response to NPC disease therapeutics. (A) Pre-post
analysis of an NPC2 patient with BMT, using Lysotracker analysis
of circulating B cells. MEFL was reduced 1 month after BMT, and by
3 months was within the pediatric control range. At 3 months after BMT,
donor chimerism developed and was detected by the presence of
2 B cell populations (inset; gated on mononuclear cells). The populations had high or low Lysotracker fluorescence, with a 50:50 distribution
of B cells between the 2 populations. HLA typing confirmed the development of 50% donor chimerism (not shown). (B) 7 patients on HPβCD
therapy (individual use INDs) were analyzed. Patients 1–4 were analyzed pre-post i.v. HPβCD (arrows denote therapy initiation points),
patients 5 and 6 were analyzed after HPβCD only, and patient 7 was
analyzed pre-post intrathecal HPβCD delivery (no i.v. administration
throughout the treatment period). (C) B cells isolated from the blood of
patients 1–4 were analyzed to determine their levels of GSL storage.
Total GSL levels were compared before and after HPβCD delivery for
each patient and plotted individually (blue; error bars derived from 3
independent HPLC analytical runs of the same samples). An average
of the 4 patients was also plotted (green; error bars derived from the
mean values for each patient). *P < 0.05; ***P < 0.001.

this point, 2 equally abundant (50:50) subpopulations of B cells
were detected, which were classified as high or low MEFL staining
(Figure 4A). This coincided with the development of 50% donor
chimerism, based on human leukocyte analysis (data not shown).
Unanticipated potential adverse response to HPβCD treatment. Finally, we investigated the effects of HPβCD therapy on B cell MEFL,
both pre-post i.v. HPβCD therapy in 4 pediatric NPC1 patients
(patients 1–4) and after i.v. HPβCD therapy in 2 additional individuals (patients 5 and 6); all 6 were being treated under individual
patient Investigational New Drug (IND) provisions (Figure 4B). In
patients 1–4, pre-post analysis showed a dramatic increase in B cell
MEFL values in response to HPβCD treatment, with patients 1–3
exceeding the NPC patient range. Analysis of patients 5 and 6 after
HPβCD therapy showed MEFL values similar to those of patients
1–3. In patients 1–4, B cells were isolated, and all 4 had increased
levels of GSL storage after HPβCD treatment (Figure 4C). We also
analyzed a single patient pre-post approximately 1 year of intrathecal HPβCD therapy (patient 7). Despite being well managed on
miglustat, with a MEFL value in the normal pediatric range prior
to intrathecal HPβCD treatment, patient 7 also showed increased
MEFL values in response to HPβCD, albeit not as great as those in
patients 1–6 with i.v. administration (Figure 4B).

average for NPC1 patients of a similar age (Figure 4A). At 1 month
after BMT, the B cell MEFL was reduced, and by 3 months after
BMT, it had moved into the control range (Figure 4A), suggestive
of cross correction and/or cell replacement with donor cells. At
1324

Discussion
In addition to disease-specific biomarkers (7), it would be useful
to have a general biomarker for measuring the degree of storage
in all lysosomal disorders, regardless of the biochemical nature
of the stored macromolecule(s). We therefore selected the probe
Lysotracker to study, as it measures relative acidic compartment
volume in live cells. An increased Lysotracker value could reflect
lysosome enlargement, increased number of lysosomes, or both.
We first validated this assay in Npc1–/– mutant mice and found
that the rate of storage in the brain and circulating B cells mirrored
each other; thus, measuring storage in circulating B cells is a suitable surrogate for measuring progression of storage in the brain.
This suggests that although absolute amounts of lipid storage differ in different cell types in NPC, the rate of storage is similar in
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Figure 5
Summary of major findings in the study.

different tissues as disease progresses, so the use of peripheral biomarkers is still informative and also minimally invasive for patients.
We then applied this assay to a multicenter, international prospective study of 106 NPC patients, spanning a 5-year period. To
our knowledge, this is the largest prospective study ever undertaken in a neurodegenerative lysosomal disorder. Typically, biomarker validation involves analysis of multiple independent clinical cohorts, each of sufficient size to provide sufficient statistical
power, in order to draw conclusions about the biomarker’s practical utility. In the case of a rare lysosomal disease such as NPC,
this is clearly not possible, due to small patient numbers. Instead,
we combined patients from 3 independent clinical cohorts from
3 countries to sufficiently power this study. Although this biomarker would be used in practice at the individual patient level,
in the present study we began with population-based analysis to
define the study cohort. We found that the clinical severity of the
total NPC study cohort spanned the severity range, and additionally revealed 6 discrete subgroups with differential rates of disease
progression. Individual untreated patients longitudinally tracked
an individual subgroup, which suggests that simply plotting total
severity against age may have prognostic value, particularly in
patients older than 5 years.
At the population level, the clear finding was that pediatric NPC
patients had significantly elevated levels of Lysotracker staining in
circulating B cells, minimally overlapping those of age-matched
controls. Similar findings were made in 2 18-month-old Tay-Sachs
disease patients compared with pediatric controls 0–6 years of
age. As lysosomal hypertrophy is a universal feature of LSDs, it is
logical to hypothesize, based on our data in more than 100 NPC1
patients and 2 Tay-Sachs patients, that relative LE/Lys volume
could represent a universal biomarker for lysosomal disorders. The

trend in NPC1 patients was for
older patients to have lower average MEFL values at the population
level than pediatric NPC1 patients,
implying a milder disease burden
in older patients, as might be predicted. In contrast, the controls
had a very tight distribution in
pediatric individuals, which broadened over time to a diverse range
of values in the adult group. This
may suggest that some individuals
develop impaired lysosomal flux as
they age, leading to an expansion
of the lysosomal system. There
was no simple age relationship,
which suggests that this is not an
inevitable consequence of aging.
Alternatively, an expanded lysosomal system in some adults in
the general population may reflect
an increased rate of substrate flux
through the lysosomal compartment. This unexpected observation merits further investigation
in the general population in order
to better understand its basis and
potential clinical significance.
However, the Lysotracker assay
was useful in adults for monitoring individual changes over time,
with patients serving as their own controls (Table 1 and ref. 3).
As the biomarker would be used in clinical practice for monitoring individual patients over time, not for population-based studies, this underscores its practical utility. When Lysotracker was
compared with the NPC disease-specific oxysterol biochemical
biomarker, there was a significant correlation with patients with
lower MEFL values. Interestingly, a subset of patients with very
high Lysotracker values did not have the predicted high level of
triol species (assuming a linear relationship), suggestive of potentially attenuated oxidative stress responses in these individuals
and highlighting the need to use multiple biomarkers in NPC.
Control and heterozygous carriers could be distinguished on the
basis of mildly elevated oxysterol levels, whereas Lysotracker values
overlapped between these 2 genotypes.
We calculated ASIS and found it to be significantly correlated
with relative lysosomal volume. Scoring with ASIS may also represent a simple tool for stratifying patients for clinical trials or
for monitoring disease progression. As the severity score used
to calculate ASIS is derived from multiple neurological clinical
measures (10), these data, in agreement with our findings in the
Npc1–/– mouse (Figure 1), are suggestive of an association between
storage in the CNS and in the hematopoietic system. Therefore,
monitoring B cell lysosomal volume is a valid minimally invasive
surrogate for storage levels in the CNS in NPC. These data also
suggest that human B cell progenitors store progressively, such
that this is reflected in the mature circulating B cell population,
as the half-life of B cells in the blood is only 36 days (11). Most
untreated NPC patients had increased relative lysosomal volumes
over time, but significant decreases were observed in the miglustattreated groups, consistent with miglustat stabilizing/slowing the
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rate of disease progression in NPC1 patients (5, 12–14). Patients in
whom pre-post analysis was performed exhibited the most marked
decrease in storage, relative to the chronically miglustat treated
group, which was relatively stable at the initiation of the study.
We also investigated the effects of 2 experimental therapies on
this biomarker. NPC2 constitutes 5% of NPC cases (15) and is
appropriate for BMT, as the NPC2 protein is a soluble, mannose6-phosphorylated protein amenable to secretion/recapture crosscorrection (16, 17). The efficacy of BMT was recently reported in
an NPC2 patient (18). We therefore monitored an NPC2 patient
pre-post BMT, and this biomarker revealed reduced storage in
peripheral B cells after BMT (cross-correction at the early time
point) and detected donor chimerism at 3 months after BMT.
Before BMT, the patient was declining, with symptoms of respiratory compromise, ataxia, and slowed development of speech. After
BMT, these symptoms improved, preceded by reduced Lysotracker staining. When symptoms returned and repeat transplant was
under consideration, Lysotracker values increased before the onset
of clinical deterioration, which suggests that this may be a sensitive biomarker for NPC2 disease.
HPβCD is an experimental drug that has shown benefit in
mouse and feline models of NPC1 (19, 20), potentially by stimulating lysosomal exocytosis, which has been demonstrated in vitro
(21). There are currently 10 NPC1 patients worldwide undergoing i.v. HPβCD therapy, of which 7 were included in this study.
Patients previously treated with miglustat (patients 1–4 and 7;
ref. 5) had reduced MEFL values, close to or within the normal
range, prior to initiation of HPβCD therapy. Paradoxically, after
HPβCD therapy, there was a pronounced increase in B cell Lysotracker fluorescence. Patients 1–6, with i.v. exposure to the drug,
developed elevated MEFL values that were similar to one another;
all but 1 were above the upper limit of the general NPC1 patient
population. Patient 7 never received HPβCD i.v.; the drug was only
administered intrathecally. However, even this individual showed
elevated MEFL values after approximately 1 year of HPβCD treatment. The magnitude of this increase was less than in patients
receiving i.v. HPβCD. These data suggest that intrathecal HPβCD
treatment resulted in exchange of HPβCD into the peripheral circulation, which was sufficient to lead to an increase in B cell MEFL
values. This assay may serve as a useful surrogate of systemic exposure to HPβCD treatment, regardless of the route of administration. We then investigated whether the increased MEFL values we
observed after HPβCD treatment reflected enhanced lipid storage
in response to HPβCD. When B cells from a subset of the patients
were isolated and analyzed biochemically, GSL levels were higher
than at the start of HPβCD therapy, suggestive of storage lipid
redistribution to B cells in response to HPβCD. These data suggest
that direct CNS delivery of HPβCD may be needed to minimize
potential peripheral side effects, although even the patient receiving intrathecal drug (patient 7) showed elevated levels, albeit to a
lesser extent than those receiving i.v. HPβCD.
The main findings of this study are summarized in Figure 5,
including differential responses to therapies. Taken together, and
based on lysosomal hypertrophy being a universal hallmark of
LSDs, our present findings suggest that this biomarker may have
broad utility as an aid to initial diagnosis (suspicion of an LSD),
for monitoring disease progression in multiple LSDs, and for
determining their differential responses to therapies. It remains
to be determined whether this peripheral blood biomarker will be
applicable in milder LSDs or in LSDs involving storage restricted
1326

to highly specialized cell types. Clinical studies are planned to test
this prospectively in a range of lysosomal disorders to determine
clinical utility more broadly.
Methods
NPC1 mice. BALB/cNctr-Npc1m1N/J (Jackson Laboratory) mice (termed Npc1–/–)
were maintained by heterozygote brother/sister matings and genotyped as
previously described (22). The Npc1–/– mouse has a lifespan of 10–12 weeks,
with neurological symptoms presenting at approximately 6 weeks of age.
Mice were group housed in ventilated cages with irradiated food and bedding
and autoclaved water available ad libitum. Control mice were Npc1+/+ mice
generated from the same litters as the Npc1–/– animals. Blood and spleens were
harvested from PBS-perfused mice under terminal anesthesia and analyzed
for flow cytometry or biochemical analysis as previously described (9).
Clinical study cohort. The 106 total NPC patients in this study were from
multiple independent international clinical cohorts from the United Kingdom, Germany, and the United States (29, 30, and 47 patients, respectively).
A further 6 NPC1 patients treated with HPβCD were also studied (in addition to 1 patient on HPβCD therapy that was part of the US cohort, giving
a total of 7 NPC1 patients on HPβCD treatment that were analyzed). The
study cohort was composed of 52 untreated patients, 54 patients on miglustat at time of first analysis, 41 heterozygous carriers, and 53 age-matched
controls. There was no standardization between centers relating to the stage
of disease when miglustat therapy was initiated, although dosing was standardized according to current clinical guidelines (23). In a subset of patients,
treatment was initiated during the study, allowing for pre-post analysis of
miglustat therapy. Longitudinal data was not collected on pediatric controls,
only on adult heterozygous carriers and adult healthy volunteers.
We also studied a pair of twins with infantile-onset Tay-Sachs, who died of
disease progression at 3 years of age. Analysis was performed at 16 months of
age, at which time they had been on off-label miglustat therapy for 5 months.
HPβCD-treated patients. Patients 1 and 2 were started on i.v. HPβCD in
April 2009 and dose escalated to 2,500 mg/kg, administered weekly. These
2 patients were also receiving, by lumbar intrathecal injection, 175 mg
HPβCD every 2 weeks starting in October 2010. Patient 3 and 4 were started
on i.v. HPβCD in December 2010 and April 2011, respectively. They were
dose escalated to 2,000 mg/kg, administered weekly. Patients 5 and 6 were
started on i.v. HPβCD in January 2010 and started on intrathecal HPβCD
in May 2010. At the time of blood sampling, they were receiving i.v. HPβCD
at a dose of 2,900 mg/kg twice per week and intrathecal HPβCD at a dose of
875 mg every 2 weeks. Patient 7 was on oral miglustat therapy (2 years) prior
to commencing intrathecal HPβCD and remained on miglustat throughout HPβCD treatment. Patient 7 was treated with HPβCD every 15 days and
commenced with 175 mg HPβCD that was increased in single-dose steps
(175, 250, 300, and 350 mg) up to a maintenance dose of 400 mg. Initially,
this patient received all HPβCD doses through lumbar puncture with i.v.
sedation; for the last 6 months of the study, HPβCD was delivered via an
Ommaya intrathecal reservoir.
BMT of an NPC2 patient. The NPC2 patient presented as a neonate with
hepatosplenomegaly and dysmorphic features. She developed progressive
neurodevelopmental delay and unexplained pulmonary disease. At 14
months of age, NPC2 was diagnosed based on filipin staining of skin fibroblasts and mutational analysis. 1 known NPC2 mutation was identified
with no second mutation found, with intronic regions yet to be sequenced.
The patient was deteriorating, and so BMT was performed at 18 months of
age using an unaffected sibling donor, as efficacy had recently been reported in another NPC2 case after BMT (18). Pre-BMT sampling and analysis
in this study was performed prior to conditioning with immunosuppressive drugs. She initially made a good recovery; however, donor chimerism
developed after the initial response (reduced MEFL value), and she clini-
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cally declined after 6 months. She was given a repeat transplant 9 months
after the initial BMT from the same donor and fully engrafted, leading
to clinical improvement. At the end of the present study, the patient was
stable and under continuous review.
Human blood collection and isolation of mononuclear cells. Venous blood was
collected into EDTA tubes, maintained at room temperature, and analyzed
within 72 hours (optimal for maintaining cell viability; data not shown).
Consent or assent was obtained from all subjects, with ethical approval in
place in each clinical center. Control samples were obtained by voluntary
donation with informed consent, or from a commercial provider where
informed consent/assent was given at the time of collection. The investigators were blinded to patient identity. Whole blood was loaded onto
Histopaque-1077 (Sigma-Aldrich), and mononuclear cells were isolated
according to the manufacturer’s instructions. The mononuclear fraction
was washed twice with Dulbecco PBS (D-PBS) before counting.
Flow cytometry. Mononuclear cells (1 × 106, in duplicate) were incubated with PE-conjugated mouse anti-human CD19 antibody (clone LT19;
Abcam) in D-PBS for 30 minutes on ice in the dark. The reaction was
stopped with 100 μl 10% BSA, and cells were spun (5 minutes at 800 g),
then either resuspended in 0.5 ml FACS buffer (0.1% BSA, 0.02M NaN3
in 1× PBS) or stained with 1 ml of 200 nM Lysotracker-green DND-26
(Invitrogen) in D-PBS for 10 minutes in the dark at room temperature.
Cells were centrifuged for 5 minutes at 800 g, resuspended in 0.5 ml FACS
buffer, and kept on ice for a maximum of 1 hour prior to flow cytometric analysis (BD Biosciences FACSCanto II). The cytometer was calibrated
using Cytometer Setup and Tracking beads (BD), and compensation was
performed using cells stained with Lysotracker and anti-mouse CompBeads (BD) stained with PE antibody using FACSDiva software (BD).
Samples were acquired with gating on singlets (FSC-H versus FSC-A) and
CD19+ events. In total, 50,000 singlet events and 10,000 singlet gate CD19+
events were collected. The mean fluorescence of the CD19+ events was calculated using FACSDiva software (BD). MEFL was calculated using 8-peak
Rainbow calibration beads (BD) using the fluorescein equivalent values
provided by the manufacturer. See Supplemental Figure 8 for details of
FACS profile and analysis.
HPLC analysis. HPLC analysis of GSLs was performed according to previously published methods (24).
Oxysterol measurements. The methodology was according to published
protocols (8). Lysotracker and oxysterol measurements were performed on
the same clinical samples for each data point.
Statistics. Logistic regression models were used to compare proportions,
Wilcoxon-Mann-Whitney and Kruskal-Wallis tests were used to compare medians, and ANOVA was used to compare means. Linear regression models (including those with splines) were fitted with maximum
likelihood methods; nonlinear regression models were fitted using least
squares methods. Latent class finite mixture regression models were fitted
using the R package flexmix (25) to define components of total clinical
score as a function of age; the number of components was chosen by minimizing the Bayesian Information Criterion. Piecewise linear regression
models were fitted using the R package SiZer (26). Adjusted P values for
pairwise comparisons were obtained using the Benjamini-Hochberg correction (27). All calculations were performed in the R language and environment for statistical computing (version 2.14.2; http://www.R-project.
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